Lobbying disclosures · Lobbying report
BBIO: fourth_quarter 2024 lobbying report
Creating Hope Reauthorization Act of 2024 - H.R. 7384 Give Kids a Chance Act of 2024 - H.R. 3433 Creating Hope Reauthorization Act of 2024 - S. 4583 March-in/Bayh-Dole Act Orphan drug policies Scientific EXPERT Act of 2024 - H.R.9979 H.R.9979 - Scientific EXPERT Act of 2024 H.R.10545 - American Relief Act, 2025
Follow BBIO- Became public
- Jul 17, 2026, 9:26 AM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 12:50 AM EST
Why this is connected
Exact legal-name match: BridgeBio Pharma, Inc. (https://www.sec.gov/Archives/edgar/data/1743881/).
Reported lobbying amounts
Expenses: $330,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/948534ff-2f3e-488f-899e-fc77ae05b765/","filing_uuid":"948534ff-2f3e-488f-899e-fc77ae05b765","filing_type":"4A","filing_type_display":"4th Quarter - Amendment","filing_year":2024,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.gov/filings/public/filing/948534ff-2f3e-488f-899e-fc77ae05b765/print/","filing_document_content_type":"text/html","income":null,"expenses":"330000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Amanda Malakoff","dt_posted":"2026-07-17T09:26:39-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3160 Porter Drive","registrant_address_2":"Suite 250","registrant_different_address":false,"registrant_city":"Palo Alto","registrant_state":"CA","registrant_zip":"94304","registrant":{"id":401107898,"url":"https://lda.gov/api/v1/registrants/401107898/","house_registrant_id":56231,"name":"BRIDGEBIO PHARMA, INC.","description":null,"address_1":"3160 Porter Drive","address_2":"Suite 250","address_3":null,"address_4":null,"city":"Palo Alto","state":"CA","state_display":"California","zip":"94304","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMANDA MALAKOFF","contact_telephone":"+1 202-543-8345","dt_updated":"2026-07-30T07:35:35.104836-04:00"},"client":{"id":57334,"url":"https://lda.gov/api/v1/clients/57334/","client_id":57334,"name":"BRIDGEBIO PHARMA, INC.","general_description":"Biotech company","client_government_entity":null,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-10-11"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Creating Hope Reauthorization Act of 2024 - H.R. 7384 Give Kids a Chance Act of 2024 - H.R. 3433 Creating Hope Reauthorization Act of 2024 - S. 4583 March-in/Bayh-Dole Act Orphan drug policies Scientific EXPERT Act of 2024 - H.R.9979 H.R.9979 - Scientific EXPERT Act of 2024 H.R.10545 - American Relief Act, 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144139,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MALAKOFF","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148343,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":"Rep. Taylor (NC-11) Intern, Leg. Correspondent, Leg. Asst. Rep. McHenry (NC-10) Policy Advisor Rep. Gingrey (GA-11) Senior Leg. Asst., Senior Policy Advisor, Leg. Director, Deputy Chief of Staff Rep. Hice (GA-10) Leg. Director","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in BBIO
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 10, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Nov 2, 2026 · disclosed Nov 10, 2026
- Nov 10, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Oct 27, 2026 · disclosed Nov 10, 2026
Traded 2 days before earnings - Oct 12, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold (partial) BridgeBio Pharma BBIO
$1K–$15K · Traded Sep 29, 2026 · disclosed Oct 12, 2026
- Jun 8, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded May 11, 2026 · disclosed Jun 8, 2026
- May 8, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Apr 29, 2026 · disclosed May 8, 2026
- Apr 7, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Mar 19, 2026 · disclosed Apr 7, 2026
- Apr 7, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Mar 18, 2026 · disclosed Apr 7, 2026
- Apr 7, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Mar 3, 2026 · disclosed Apr 7, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.